Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model

European Journal of Pharmacology

Volumn 690, Issue 1-3, 2012, Pages 176-182

  Zapata Sudo, Gisele ^a   Pontes, Luana Braga ^a   Silva, Jaqueline Soares Da ^a   Lima, Lídia Moreira ^a   Nunes, Isabelle Karine Da Costa ^a   Barreiro, Eliezer Jesus ^a   Sudo, Roberto Takashi ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

(N 2 (34 dimethoxyphenyl) ethyl ; benzenesulfonamide; LASSBio 965; Monocrotaline; Phosphodiesterase; Pulmonary arterial hypertension; Rhokinase

Indexed keywords

BENZENESULFONAMIDE DERIVATIVE; LASSBIO 965; MILRINONE; MONOCROTALINE; N [2 (3,4 DIMETHOXYPHENYL)ETHYL]BENZENESULFONAMIDE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; ROLIPRAM; SILDENAFIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; HEART LEFT VENTRICLE; HEART RIGHT VENTRICLE PRESSURE; HEART VENTRICLE SEPTUM; HEART WEIGHT; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; DISEASE MODELS, ANIMAL; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; PULMONARY ARTERY; RATS; RATS, WISTAR; SULFONAMIDES; VENTRICULAR PRESSURE;

EID: 84864494066     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.05.043     Document Type: Article

References (44)

1. K. Abe, H. Shimokawa, K. Morikawa, T. Uwatoku, K. Oi, Y. Matsumoto, T. Hattori, Y. Nakashima, K. Kaibuchi, K. Sueishi, and A. Takeshit Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats Circ. Res. 94 2004 385 393
2. S. Archer, and S. Rich Primary pulmonary hypertension: a vascular biology and translational research Work in progress Circulation 102 2000 2781 2791
3. A.A. Artiñano, and V.L.M. Gonzalez Endotelial dysfunction and hypertensive vasoconstriction Pharmacol. Res. 40 1999 113 124
4. S.A. Barman, S. Zhu, and R.E. White RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension Vasc. Health Risk Manage. 5 2009 663 671
5. V. Boswell-Smith, D. Spina, and C.P. Page Phosphodiesterase inhibitors Br. J. Pharmacol. 147 2006 S252 S257
6. K. Budzyn, R.M. Ravi, A.A. Miller, and C.G. Sobey Mechanisms of augmented vasoconstriction induced by 5-hydroxytryptamine in aortic rings from spontaneously hypertensive rats Br. J. Pharmacol. 155 2008 210 216
7. L.T. Chang, C.K. Sun, J.J. Sheu, C.H. Chiang, A.A. Youssef, F.Y. Lee, C.J. Wu, and H.K. Yip Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model Circ. J. 72 2008 825 831
8. I. Chazova, J.E. Loyd, V.S. Zhdanov, J.H. Newman, Y. Belenkov, and B. Meyrick Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension Am. J. Pathol. 146 1995 389 397
9. M.J. Davis, and M.A. Hill Signaling mechanisms underlying the vascular myogenic response Physiol. Rev. 79 1999 387 423
10. B. Deb, K. Bradford, and R.G. Pearl Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension Crit. Care Med. 28 2000 795 799
11. Z. Deng, J.H. Morse, S.L. Slager, N. Cuervo, K.J. Moore, G. Venetos, S. Kalachikov, E. Cayanis, S.G. Fischer, R.J. Barst, S.E. Hodge, and J.A. Knowles Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene Am. J. Hum. Genet. 67 2000 737 744
12. T.P. Dousa Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney Kidney Int. 55 1999 29 62
13. S. Eddahibi, M. Humbert, E. Fadel, B. Raffestin, M. Darmon, F. Capron, G. Simonneau, P. Dartevelle, M. Hamon, and S. Adnot Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension J. Clin. Invest. 108 2001 1141 1150
14. D.M. Essayan Cyclic nucleotide phosphodiesterases J. Allergy Clin. Immunol. 108 2001 671 680
15. A. Galindo, M.L. Vargas, J.G. Estañ, T. Fuentes, and J. Hernández Synergistic interaction of diazepam with 3′,5′- cyclic adenosine monophosphate-elevating agents on rat aortic rings Eur. J. Pharmacol. 428 2001 269 275
16. H.A. Ghofrani, R. Wiedemann, F. Rose, R.T. Schermuly, H. Olschewski, N. Weissmann, A. Gunther, D. Walmrath, W. Seeger, and F. Grimminger Sildenafil for treatmente of lung fibrosis and pulmonary hypertension: a randomized controlled trial Lancet 360 2002 895 900
17. P.M. Hassoun, L. Mouthon, J.A. Barberà, S. Eddahibi, S.C. Flores, F. Grimminger, P.L. Jones, M.L. Maitland, E.D. Michelakis, N.W. Morrell, J.H. Newman, M. Rabinovitch, R. Schermuly, K.R. Stenmark, N.F. Voelkel, J.X.J. Yuan, and M. Humbert Inflammation, growth factors, and pulmonary vascular remodeling J. Am. Coll. Cardiol. 54 2009 S10 S19
18. P. Hervé, J.M. Launay, M.L. Scrobohaci, F. Brenot, G. Simonneau, P. Petitpretz, P. Poubeau, J. Cerrina, P. Duroux, and L. Drouet Increased plasma serotonin in primary pulmonary hypertension Am. J. Med. 99 1995 249 254
19. M Humbert, O Sitbon, and G. Simonneau Treatment of pulmonary arterial hypertension N. Eng. J. Med. 351 2004 1425 1436
20. R.J. Huxtable Activation and pulmonary toxicity of pyrrolizidine alkaloids Pharmac. Ther. 47 1990 371 389
21. M. Izikki, B. Raffestin, J. Klar, A. Hatzelmann, D. Marx, H. Tenor, P. Zadigue, S. Adnot, and S. Eddahibi Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats J. Pharmacol. Exp. Ther. 330 2009 54 62
22. H. Liu, Z.Y. Liu, and Q. Guan Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats Interact. Cardiovasc. Thorac. Surg. 6 2007 608 613
23. Y.C. Lo, H.H. Tsou, R.J. Lin, D.C. Wu, B.N. Wu, Y.T. Lin, and I.J. Chen Endothelium-dependent and -independent vasorelaxation by a theophylline derivative MCPT: roles of cyclic nucleotides, potassium channel opening and phosphodiesterase inhibition Life Sci. 76 2005 931 944
24. C. Lugnier, P. Schoeffter, A. Le Bec, E. Strouthou, and J.C. Stoclet Selective inhibition of cyclic nucleotide phosphodiesterase of human, bovine and rat aorta Biochem. Pharmacol. 35 1986 1743 1751
25. E. Mawatari, M. Hongo, A. Sakai, F. Terasawa, M. Takahashi, Y. Yazaki, O. Kinoshita, and U. Ikeda Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering Clin. Exp. Pharmacol. Physiol. 34 2007 594 600
26. V.V. McLaughlin, S.L. Archer, D.B. Badesch, R.J. Barst, H.W. Farber, J.R. Lindner, M.A. Mathier, M.D. McGoon, M.H. Park, R.S. Rosenson, L.J. Rubin, V.F. Tapson, and J. Varga ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American college of cardiology foundation task force on expert consensus documents and the American heart association: developed in collaboration with the American college of chest physicians, American thoracic society, Inc., and the pulmonary hypertension association Circulation 119 2009 2250 2294
27. E. Michelakis, W. Tymchak, D. Lien, L. Webster, K. Hashimoto, and S. Archer Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide Circulation 105 2002 2398 2403
28. M. Miyahara, M. Ito, H. Itoh, T. Shiraishi, N. Isaka, T. Konishi, and T. Nakano Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021 Eur. J. Pharmacol. 284 1995 25 33
29. H. Mochida, H. Inoue, M. Takagi, T. Noto, K. Yano, and K. Kikkawa Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta Eur. J. Pharmacol. 440 2002 45 52
30. D. Patterson, G.T. McInnes, J. Webster, M.M. Mitchell, and T.M. MacDonald Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension Br. J. Clin. Pharmacol. 62 2006 280 287
31. V. Petkov, W. Mosgoeller, R. Ziesche, M. Raderer, L. Stiebellehner, K. Vonbank, G.C. Funk, G. Hamilton, C. Novotny, B. Burian, and L.H. Block Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension J. Clin. Invest. 111 2003 1339 1346
32. G.G. Pietra, W.D. Edwards, J.M. Kay, S. Rich, J. Kernis, B. Schloo, S.M. Ayres, E.H. Bergofsky, B.H. Brundage, and K.M. Detre Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the national heart, lung, and blood institute, primary pulmonary hypertension registry Circulation 80 1989 1198 1206
33. D.P. Rotella Phosphodiesterase 5 inhibitors: current status and potential applications Nat. Drugs Discovery 1 2002 674 682
34. B.K. Sastry, C. Narasimhan, N.K. Reddy, and B.S. Raju Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study J. Am. Coll. Cardiol. 43 2004 1149 1153
35. R.T. Schermuly, K.P. Kreisselmeier, H.A. Ghofrani, A. Samidurai, S. Pullamsetti, N. Weissmann, C. Schudt, L. Ermert, W. Seeger, and F. Grimminger Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension Circ. Res. 94 2004 1101 1108
36. H. Shimokawa Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases J. Cardiovasc. Pharmacol. 39 2002 319 327
37. G. Simonneau, I.M. Robbins, M. Beghetti, R.N. Channick, M. Delcroix, C.P. Denton, C.G. Elliott, S.P. Gaine, M.T. Gladwin, Z.C. Jing, M.J. Krowka, D. Langleben, N. Nakanishi, and R. Souza Updated clinical classification of pulmonary hypertension J. Am. Coll. Cardiol. 54 2009 S43 S54
38. Sun, D., Perkins, E.L., Tugendreich, S., 2003. Modulators of Rho C activity. WO 03/043578 - PCT/US02/37098.
39. T. Thenappan, S.J. Shah, S. Rich, S.L. Archer, and M. Gomberg-Maitland Survival of patients with pulmonary arterial hypertension in the current era: validation of the national institute of health (NIH) risk stratification equation Chest 132 2007 487S
40. H.A. Toque, F.Z. Mónica, R.P. Morganti, G. De Nucci, and E. Antunes Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle Eur. J. Pharmacol. 645 2010 158 164
41. R.C. Trembath, J.R. Thomson, R.D. Machado, N.V. Morgan, C. Atkinson, I. Winship, G. Simonneau, N. Galie, J.E. Loyd, M. Humbert, W.C. Nichols, N.W. Morrell, J. Berg, A. Manes, J. McGaughran, M. Pauciulo, and L. Wheeler Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia NEJM 345 2001 325 334
42. R.M. Tuder, C.D. Cool, M.W. Geraci, J. Wang, S.H. Abman, L. Wright, D. Badesch, and N.F. Voelkel Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension Am. J. Respir. Crit. Care Med. 159 1999 1925 1932
43. J. Wharton, J.W. Strange, G.M. Möller, E.J. Growcott, X. Ren, A.P. Franklyn, S.C. Phillips, and M.R. Wilkins Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells Am. J. Respir. Crit. Care Med. 172 2005 105 113
44. B.S. Zuckerbraun, B.Y. Chin, B. Wegiel, T.R. Billiar, E. Czsimadia, J. Rao, L. Shimoda, E. Ifedigbo, S. Kanno, and L.E. Otterbein Carbon monoxide reverses established pulmonary hypertension J. Exp. Med. 203 2006 2109 2211